Woman reading the Dagens Industri newspaper

Press releases

Category
Year

Interim Report July – September 2018 Regulatory

October 26, 2018
“Broad based progress”
Read more

Oncopeptides to host a Capital Markets Day in New York on December 14th

October 25, 2018
Stockholm – October 25, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will host a Capital Markets Day on December 14th between 8.30-11.00 AM ET in New York. Speakers will include Jakob Lindberg, Chief Executive Officer, other members of management and Professor Paul G Richardson, Dana-Farber Cancer Institute, Clinical Program Leader & Director of Clinical Research, Jerome Lipper Multiple Myeloma Center. The event will also be webcasted. A detailed program will be published in beginning of December
Read more

Nomination Committee appointed in respect of AGM 2019 in Oncopeptides

October 15, 2018
Stockholm - October 15, 2018 - According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held on 17 May 2018, the Nomination Committee for the annual general meeting 2019 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of 28 September, along with the Chairman of the Board of Directors
Read more

Oncopeptides to present at the Jefferies London Healthcare Conference on November 14th

October 12, 2018
Stockholm – October 12, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will present at Jefferies London Healthcare Conference on November 14th at 3.20 PM local time (GMT), the presentation will be webcasted
Read more

First patient starts treatment with Ygalo® in Oncopeptides’ Phase II study BRIDGE in RRMM patients with renal impairment

September 18, 2018
Stockholm – 18 September 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the first patient has started treatment in the company's Phase II BRIDGE trial designed to study the Pharmacokinetics (PK), safety and efficacy of Ygalo® in combination with dexamethasone in multiple myeloma patients with renal impairment. Multiple myeloma commonly results in deteriorating renal function. This makes BRIDGE an important study to show treating physicians how Ygalo® can be used in Relapsed Refractory Multiple Myeloma (RRMM) patients with renal impairment
Read more

Number of shares and votes in Oncopeptides Regulatory

August 31, 2018
Stockholm —31 August, 2018 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company’s incentive programs
Read more

Anders Martin-Löf has been appointed as the new CFO of Oncopeptides Regulatory

August 9, 2018
Stockholm – August 9, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Anders Martin-Löf, has been appointed as the new CFO of Oncopeptides and will join the company in November
Read more

Number of shares and votes in Oncopeptides Regulatory

July 31, 2018
Stockholm —31 July, 2018 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company’s incentive programs
Read more

Interim Report April-June 2018 Regulatory

July 13, 2018
“General knowledge and understanding of Oncopeptides and our clinical strategy has greatly increased during the spring”
Read more

Oncopeptides present updated interim data from the ongoing HORIZON trial with Ygalo® at the 23rd Congress of The European Hematology Association (EHA) Regulatory

June 15, 2018
Stockholm – June 15, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they are presenting updated interim data with Ygalo® (melflufen) from the ongoing HORIZON trial at the 23rd EHA congress in Stockholm. The updated phase II-data show a clinical data set with an Overall Response Rate (ORR) of 32.1% and a Clinical Benefit Rate (CBR) of 39.3% with Ygalo® in relapsed/refractory multiple myeloma patients refractory to pomalidomide and/or daratumumab after failing on immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs)
Read more